Eisai postpones NerBloc launch
NerBloc, a botulinum toxin type B neuromuscular-blocking agent, has been approved by the Japanese regulatory authority in 21 January 2011. NerBloc has showed improvement in TWSTRS (Toronto Western
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.